A groundbreaking clinical study using focused ultrasound (FUS) technology for the treatment of Alzheimer's disease has been reported in The New England Journal of Medicine, announced by Insightec, a global healthcare company.
Conducted with WVU Rockefeller Neuroscience Institute (RNI), the study presents a novel treatment approach combining focused ultrasound to open the blood-brain barrier with systemic monoclonal antibody infusion.
This method significantly enhances the removal of cerebral beta-amyloid, a key indicator of Alzheimer's disease, showing potential in targeted drug delivery for neurological conditions.
Really Important Advancement
Insightec's CEO, Maurice R. Ferré, MD, highlights the challenge of drug delivery across the blood-brain barrier, emphasizing the importance of this advancement.
Ali Rezai, MD, of RNI, expresses optimism about the study's results and the ongoing collaboration with Insightec. This breakthrough offers new hope in treating the 6.7 million Americans affected by Alzheimer's disease, marking a significant stride in addressing this critical medical need.
Neither Insightec nor Biogen, the manufacturer of aducanumab, sponsored the research.
